PROMETIC (1)

symetry121

(0)

56029 Reads | 19 Comments | 3 People call this a favourite

• Add blog to favourites

• T.PLI:New Beacon report, price target 3.50$

  
  
  769 Reads | 1 Comment | June 19, 2014
  
  

  ProMetic announced that it has successfully  completed its PBI-4050 Phase 1 clinical trial in 40  healthy volunteers.     The objective of the oral, double blind, placebo  controlled, single ascending dose study was to  demonstrate safety and tolerability.     ProMetic can now move to the next stage of clinical ...

  ---

• T.PLI:NR:PLI Successfully Completes its PBI-4050 Phase I

  
  
  315 Reads | 0 Comments | June 18, 2014
  
  

  ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial - PBI-4050 well tolerated; no serious adverse events reported - PBI-4050 set to target orphan conditions in addition to diabetic patients with chronic kidney disease LAVAL, QUEBEC--(Marketwired - June 18, 2014) - ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the "Corporation"...

  ---

• T.PLI:NR,other deal!$5.6 Million Purchase Order from Octapharma

  
  
  483 Reads | 0 Comments | June 5, 2014
  
  

  ProMetic Receives a $5.6 Million Purchase Order from Octapharma   LAVAL, QUEBEC--(Marketwired - June 5, 2014) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today that it has received a $5.6 million purchase order under its ongoing supply agreement with Octapharma, a leading, Swiss, independent...

  ---

• T.PLI: insider loading up.......

  
  
  645 Reads | 0 Comments | May 29, 2014
  
  

  As of 11:59pm ET May 28th, 2014 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Price May 28/14 May 22/14 Hakim, Raymond Manuel Direct Ownership Common Shares 10...

  ---

• T.PLI:must read info from IR(from Fred)

  
  
  372 Reads | 0 Comments | May 16, 2014
  
  

  Interesting news in Fred's comments today   Just got this from Fred. Very interesting that 1 cohort of patients have been included in the phase 1 4050 trial!! Obviously the results have been good or they would never have gone near patients IMHO. The results could be more interesting than we think. PLI will be the standard for others whio wish to produce plasminogen!! I...

  ---

• T.PLI: major q1 points

  
  
  266 Reads | 0 Comments | May 14, 2014
  
  

  2014 revenues expected to significantly exceed 2013 revenues PBI-4050 clinical program to enroll diabetic patients with chronic kidney disease in H2 2014 IVIG and Plasminogen clinical programs and regulatory pathways confirmed in pre-IND meeting with the FDA - initiation in patients expected in H2 2014 Alpha 1 Antitrypsin initiation in patients expected in Q1 2015...

  ---

• T.PLI:Paradigm raises price target to 2.80$

  
  
  381 Reads | 0 Comments | May 14, 2014
  
  

  Prometic Life Sciences Price Target Raised to C$2.80 at Paradigm Capital (PLI) Posted by Pezhman Azimi on May 14th, 2014 // No Comments   Prometic Life Sciences (TSE:PLI) had its price objective raised by Paradigm Capital from C$2.25 to C$2.80 in a research report released on Monday morning, Analyst RN reports. Paradigm...

  ---

• T.PLI:q1 is out! Revenues up again...

  
  
  284 Reads | 1 Comment | May 14, 2014
  
  

  ---